中国儿童肾母细胞瘤CCCG-WT-2015方案多中心临床研究
该前瞻性多中心研究总结了CCCG-WT-2015方案治疗288例初发肾肿瘤患儿(其中WT 261例)的疗效。结果显示FHWT和UFHWT的3年EFS分别为(88.9±2.1)%和(80.0±17.9)%,优于WT-2009方案;病理类型和治疗结束时未达CR是独立预后因素。
要点
- CCCG-WT-2015方案治疗儿童肾肿瘤生存优于WT-2009方案。
- Ⅲ/Ⅳ期FHWT有放疗指征者中,M方案化疗替代放疗的3年EFS与放疗组无显著差异。
- 病理类型和治疗结束时是否达CR是独立预后影响因素。
核心结论
- CCCG-WT-2015方案较WT-2009方案改善了儿童肾肿瘤预后,可扩大协作组应用。
研究设计与样本
- 前瞻性研究,在CCCG-WT-2009方案基础上修正建立WT-2015方案,总结14家协作组成员单位2015年9月至2018年12月明确诊断的288例初发肾肿瘤患儿临床资料。
主要发现
- 288例肾肿瘤中WT 261例,其中FHWT 254例(97.3%),UFHWT 7例(2.7%)。
- FHWT、UFHWT的3年EFS分别为(88.9±2.1)%、(80.0±17.9)%,优于WT-2009方案的81.2%、71.7%。
- Ⅲ、Ⅳ期FHWT有放疗指征者96例,76例实施放疗,20例因未放疗升至M方案化疗;放疗与未放疗患儿3年EFS分别为(84.7±4.3)%及(84.7±8.1)%,差异无统计学意义(χ²=0.015,P=0.902)。
- 肾透明细胞肉瘤22例和肾横纹肌样瘤5例,3年EFS分别为(94.4±5.4)%及(20.0±17.9)%。
- 单因素分析发现病理类型(χ²=44.329,P<0.01)和治疗结束时未达CR(χ²=49.459,P<0.01)是独立预后影响因素。
关键数值与推荐
- FHWT 3年EFS为(88.9±2.1)%,UFHWT为(80.0±17.9)%。
- Ⅲ/Ⅳ期FHWT有放疗指征者中,放疗组与M方案化疗组3年EFS分别为(84.7±4.3)%和(84.7±8.1)%(P=0.902)。
- 肾透明细胞肉瘤3年EFS为(94.4±5.4)%,肾横纹肌样瘤为(20.0±17.9)%。
临床怎么用
- 儿童肾肿瘤可应用CCCG-WT-2015方案进行分层治疗。
- Ⅲ/Ⅳ期FHWT有放疗指征者,在特定条件下可考虑M方案化疗替代放疗。
- 治疗中应关注病理类型及治疗结束时是否达到CR以评估预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To summarize the effect of Chinese Children's Cancer Group (CCCG) Wilms tumor (WT)-2015 protocol. Methods: This was a prospective study. CCCG-WT-2015 protocol was revised on the basis of the CCCG-WT-2009 protocol. Clinical data of 288 children diagnosed with newly diagnosed kidney neoplasms in fourteen pediatric centers between September 2015 to December 2018 were summarized. The age of onset, distribution of pathological subtypes, staging, curative effect and prognostic factors of these children were analyzed. Kaplan-Meier method was used for survival curve and Log-Rank method was used for univariate analysis. Results: Among 288 cases with kidney neoplasms, there were 261 cases of WT, including 254 cases (97.3%) with favorable histology (FH) WT and 7 cases (2.7%) with unfavorable histology WT (UFHWT). The 3 year events free survival (EFS) rate for FHWT and UFHWT were (88.9±2.1)% and (80.0±17.9)%, which were better than that in WT-2009 (81.2% and 71.7%). In the 96 cases of stage Ⅲ/Ⅳ FHWT with indications for radiotherapy, 76 cases received radiation, another 20 cases received M protocol chemotherapy (cyclophosphamide, etoposide, gentamycin, vincristine and adriamycin) instead of radiation. The 3 year EFS rate for these two groups were (84.7±4.3)% and (84.7±8.1)%(χ2=0.015, P=0.902). There were 22 renal clear cell sarcoma and 5 malignant rhabdoid tumor, 3 year EFS rate of them was (94.4±5.4)% and (20.0±17.9)%. Univariate analysis was performed for age, gender, pathological type, stage, whether rupture occurred during operation, whether complete remission (CR) occurred at the end of treatment and radiotherapy. Pathological types (χ2=44.329,P<0.01) and failure to achieve CR at the end of the treatment (χ2=49.459,P<0.01) were independent factor for predicting survival. Conclusion: Compared with CCCG-WT-2009, treatment of renal tumors in CCCG-WT-2015 study yielded good survival outcome, which can be further applied. 目的: 总结中国小儿肿瘤专业委员会(CCCG)肾母细胞瘤(WT)-2015方案的疗效。 方法: 前瞻性研究,在CCCG-WT-2009方案基础上修正建立WT-2015方案。总结2015年9月至2018年12月在14家协作组成员单位明确诊断的288例初发肾肿瘤患儿的临床资料。分析儿童肾肿瘤的发病年龄、病理亚型分布、分期、疗效及预后因素。生存曲线应用Kaplan-Meier法,单因素分析应用Log-Rank法。 结果: 288例肾肿瘤中WT 261例,其中良好组织学型(FH)WT 254例, 占97.3%,间变型(UFH)WT 7例,占2.7%。FHWT、UFHWT 3年无事件生存率(EFS)分别为(88.9±2.1)%、(80.0±17.9)%,优于WT-2009方案的81.2%、71.7%。Ⅲ、Ⅳ期FHWT有放疗指征者96例,其中76例实施放疗,20例因未放疗升至M方案化疗(环磷酰胺、依托泊苷、更生霉素、长春新碱、阿霉素),放疗与未放疗患儿3年EFS分别为(84.7±4.3)%及(84.7±8.1)%,预后差异无统计学意义(χ²=0.015,P=0.902)。肾肉瘤包括肾透明细胞肉瘤 22例和肾横纹肌样瘤 5 例。3年EFS分别为(94.4±5.4)%及(20.0±17.9)%。将年龄、性别、病理类型、分期、手术中破溃否、治疗结束是否达到完全缓解(CR)、放疗否进行预后单因素分析,结果发现病理类型(χ²=44.329,P<0.01)和治疗结束时是否达到CR(χ²=49.459,P<0.01)是独立预后影响因素。 结论: CCCG-WT-2015方案与WT-2009方案相比,预后改善,可扩大协作组对象应用本方案。.
引用
- Zhang AA, Tang JY, Xu M, et al. [Multicenter clinical study on the diagnosis and treatment of childhood renal tumor]. Zhonghua Er Ke Za Zhi. 2021. PMID: 33657693. doi:10.3760/cma.j.cn112140-20200707-00698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。